Trials / Completed
CompletedNCT00147303
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Sarpogrelate is an antiplatelet agent that decreases 5-hydroxytryptamine( 5-HT )levels in platelets via blockade of 5-HT2 receptors, has been used in atherosclerotic peripheral arterial disease. The present double-blind controlled clinical pharmacology study was performed on 45 patients with cerebral infarction, who were given 75, 150, or 300 mg three times daily of sarpogrelate for 7 days in order to evaluate the dose-response relationship in terms of the precisely measured inhibition of platelet aggregation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCI-9042 |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2005-09-07
- Last updated
- 2015-04-10
Source: ClinicalTrials.gov record NCT00147303. Inclusion in this directory is not an endorsement.